Journal of Oncology Pharmacy Practice最新文献

{"title":"Collaboration between clinical pharmacists and physicians to manage drug-related problems in an adult hematopoietic stem cell transplantation unit.","authors":"Mehmet Ali Dal, Aysu Selcuk, Ilker Ates, Gulcan Kokcu, Merve Yuksel, Merve Aydogan, Meltem Kurt Yuksel","doi":"10.1177/10781552261505028","DOIUrl":"https://doi.org/10.1177/10781552261505028","url":null,"abstract":"<p><p>IntroductionThis study aimed to determine drug-related problems and identify potential solution in collaboration with clinical pharmacists and specialist physicians at an adult hematopoietic stem cell transplantation unit in Türkiye.MethodsThis is a prospective observational study that included patients with autologous and allogeneic HSCT (Hematopoietic Stem cell Transplantation) admitted to a university hospital HSCT unit in Türkiye due to the disease or complications between June 2023 and January 2024. Drug-related problems (DRPs) were identified during a comprehensive medication review performed by a single clinical pharmacist (specialist trainee) supervised by a senior clinical pharmacist, using the Turkish version of the v.9.1 Pharmaceutical Care Network Europe (PCNE) classification. The potential DRPs were reported to the physicians to discuss their agreement on the possible solutions. The number of DRPs, agreement rate of the solutions and status of interventions were recorded.ResultsThe study enrolled 66 adult patients with a median age of 54.5 years (54.5% male). A total of 156 potential DRPs were identified among the patients at HSCTU with an average of 2.4 DRPs per patient. The proportion of patients experiencing at least one DRP was 89% in the autologous HSCT group and 97% in the allogeneic HSCT group. Patients with allogeneic HSCT experienced a significantly higher number of DRPs compared to those with autologous HSCT. Among DRPs, drug-drug interactions (DDIs) were common (56.0%). The majority of the recommendations made by the clinical pharmacist in training were accepted by the physicians (86.5%). Overall, 84.0% of DRPs were solved in collaboration with clinical pharmacists and physicians.ConclusionsDDIs were common DRPs among patients with HSCT. Most of the clinical pharmacists' recommendations were accepted. A substantial number of potential DRPs were effectively resolved through direct collaboration between the clinical pharmacist and physicians.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261505028"},"PeriodicalIF":1.3,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of a pharmacist-led pharmacogenomic service on test capture rates in oncology: A retrospective pre-post cohort study, 2024-2026.","authors":"Aubrey Norgren, Hunter Eldien, Joseph Broughton, Chodisha Chakrapani, Abdul R Shour","doi":"10.1177/10781552261505496","DOIUrl":"https://doi.org/10.1177/10781552261505496","url":null,"abstract":"<p><p>BackgroundPharmacogenomic (PGx) testing can support clinical decision-making to reduce toxicity associated with commonly used oncology therapies. However, PGx testing remains underutilized in oncology practice due to lack of personnel to coordinate testing. We evaluated whether the implementation of a pharmacist-led PGx service increased PGx testing among oncology patients.MethodsWe used a retrospective cohort study to compare outcomes from the pre-and post-intervention periods following implementation of a pharmacist-led PGx service within our Duluth oncology clinic, Minnesota-USA. EHR/laboratory data were extracted on adult cancer patients with planned/receiving 5-fluorouracil, capecitabine, or irinotecan between September 1, 2024, and March 31, 2026. The primary outcome was PGx capture, defined as the rate of patients who received PGx testing prior to chemotherapy initiation. Secondary outcomes included tests with actionable results and the proportion leading to therapy modification. Descriptive statistics, Chi-square test, Mann-Whitney U test, and adjusted (age and sex as covariates) logistic regression were used. All analyses were performed using SPSS (IBM 29.0) and RStudio (2025.09.1 + 401) with a statistical significance at ≤0.05.ResultsA total of 184 (N) eligible patients were included, with 107 in the pre-implementation group and 77 in the post-implementation group. PGx test capture rates increased from 25.2% in the pre-implementation group to 53.2% post-implementation (P < 0.001). In adjusted analysis, the post-implementation group remained significantly associated with higher PGx testing (OR = 3.40, 95% CI: (1.82,6.36))ConclusionImplementation of a pharmacist-led PGx workflow substantially increased testing. Integration of pharmacists into oncology PGx services may improve the identification of clinically relevant variants and support medication optimization.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261505496"},"PeriodicalIF":1.3,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ruxolitinib for graft-versus-host disease prophylaxis following tacrolimus toxicity: A case series.","authors":"Nidhi Kanchan, Janine Martino, Dimitrios Tzachanis, Ila M Saunders","doi":"10.1177/10781552261504757","DOIUrl":"https://doi.org/10.1177/10781552261504757","url":null,"abstract":"<p><p>IntroductionThe data on the safety and feasibility of transitioning from tacrolimus to ruxolitinib for graft-versus-host disease (GVHD) prophylaxis in the early post-allogeneic hematopoietic stem cell transplantation (allo-HCT) period is lacking. Optimal dosing and timing of ruxolitinib remains unclear.Case ReportWe describe four allo-HCT recipients who required early tacrolimus discontinuation due to neurotoxicity (n = 2) or nephrotoxicity (n = 2) and were transitioned to ruxolitinib for GVHD prophylaxis. The patients ranged from 23 to 74 years of age and received reduced-intensity conditioning with standard post-transplant cyclophosphamide-based prophylaxis. Tacrolimus was discontinued between Days +27 and +44.Management and OutcomesRuxolitinib was initiated between Days +29 and +53 at doses ranging between 5 to 15 milligrams per day with the use of a short prednisone bridge in one patient. All four patients experienced resolution of their tacrolimus-related toxicity, and no acute or chronic GVHD events were observed at last follow-up. The primary ruxolitinib-associated adverse event was cytopenia, which was expected. Full or near full chimerism was maintained in all patients.DiscussionThis case series provides early evidence for a safe switch from tacrolimus to ruxolitinib for GVHD prophylaxis in the post-allo-HCT setting with effective GVHD control. Ruxolitinib 5 to 15 milligrams per day appear reasonable when tacrolimus discontinuation is necessary. Prospective studies are needed to define optimal dosing and transition strategies.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261504757"},"PeriodicalIF":1.3,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149334206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial disparities in treatment patterns in patients with non-small cell lung cancer before and after approval of immune checkpoint inhibitors: A population-based study.","authors":"Ashwini Arunachalam, Soko Setoguchi, Jason Roy, Jyoti Malhotra, Judith M Graber","doi":"10.1177/10781552261500132","DOIUrl":"https://doi.org/10.1177/10781552261500132","url":null,"abstract":"<p><p>BackgroundThe introduction of immune checkpoint inhibitors (ICIs) has changed the treatment landscape for advanced non-small cell lung cancer (NSCLC). This study investigates racial disparities in the receipt of systemic therapy among patients with advanced NSCLC in periods before and after approval of ICIs.MethodsThis retrospective cohort study analyzed data on patients with advanced NSCLC, comparing patient characteristics and systemic therapy receipt before and after the introduction of ICIs. The study population included White, Black, and Asian patients. We used logistic regression to calculate crude and adjusted odds ratios (ORs) for the initiation of guideline-recommended systemic therapy.ResultsSystemic therapy use increased for all racial groups in the post-ICI era. However, disparities in the type of treatment and time to initiation persisted. In the pre-ICI period, after adjustment for covariates, Asian patients had higher odds (OR 2.33, 95% CI 1.82-2.98), and Black patients had similar odds (OR 1.06, 95% CI 0.81-1.40) of initiating therapy compared with White patients. In the post-ICI period, there were no statistically significant differences in the adjusted odds of initiating therapy among the racial groups.ConclusionThe introduction of ICIs was associated with an overall increase in the receipt of systemic therapy for advanced NSCLC and a reduction in racial disparities in the treatment initiation. However, differences in the types of therapy received and time to treatment initiation remain.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261500132"},"PeriodicalIF":1.3,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149322308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antibody-drug conjugate use and spending in the United States, 2013-2022.","authors":"Paul R Shafer, Hooman Y Farsani, Haoran Tao, Aaron P Mitchell","doi":"10.1177/10781552261503965","DOIUrl":"10.1177/10781552261503965","url":null,"abstract":"<p><p>IntroductionAntibody-drug conjugates (ADC) are a class of pharmaceuticals that combine monoclonal antibodies with cytotoxic drugs, aiming to treat cancer while minimizing off-target toxicity. They are a small class but growing in importance, as evidenced by high commercial investment. Our objective is to describe the use of and spending on ADCs across commercial and public payers in the US.MethodsWe used four data sources to capture ADC use and costs in the US from 2013 to 2022-1) Merative™ MarketScan^® Commercial Database, 2) Centers for Medicare and Medicaid (CMS) Medicaid State Drug Utilization Data, 3) CMS Medicare Part B Spending by Drug, and 4) Medicare Part D Spending by Drug.ResultsTraditional Medicare (Parts B and D) spent over $3.6 million per 100,000 enrollees on ADCs in 2022 compared with over $1.1 million per 100,000 enrollees in a national sample of commercial insurance plans (MarketScan). Irrespective of differences in volume, commercial payers were paying approximately 91% more for ADCs per patient than Medicare Part B in 2022. Although we could not measure Medicaid spending on ADCs, relative growth in Medicaid prescription volume per 100,000 enrollees over the study period was also strong, increasing more than six times.ConclusionsUse of ADCs has increased dramatically in recent years, with rates of use more than tripling within Medicare Part B and more than doubling within employer-sponsored coverage from 2019 to 2022. This growth coupled with wide variation in reimbursement between ADCs and across public and private payers suggests a need for further evidence of comparative and cost effectiveness in this growing class, particularly as it expands to non-oncological uses, to inform clinical decision making and improve patient outcomes.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261503965"},"PeriodicalIF":1.3,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149322307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enzalutamide alone or combined with other pharmacologic agents for metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.","authors":"Yeison Cruz Castillo, Alejandro Chen Liang, Victor M Samperio, Alexa Bentley, Elizabeth Olive Roberts Trinidad, Ion Codreanu, Constantin A Dasanu","doi":"10.1177/10781552261497638","DOIUrl":"https://doi.org/10.1177/10781552261497638","url":null,"abstract":"<p><p>BackgroundMetastatic castration-resistant prostate cancer (mCRPC) remains driven by persistent androgen receptor signaling. Although enzalutamide (ENZ) is widely used, the incremental benefit of adding other agents remains uncertain. We evaluated the efficacy and safety of specific pharmacologic agents added to ENZ in randomized trials.MethodsWe systematically searched PubMed/MEDLINE, Web of Science, CINAHL, and Scopus through September 2026 following PRISMA guidelines (PROSPERO: CRD420251231232). RCTs comparing ENZ plus another pharmacologic agent with ENZ monotherapy in mCRPC were included. Analyzed outcomes included overall survival (OS), progression-free survival (PFS), radiographic PFS (rPFS), PSA progression, and adverse events. Random-effects meta-analyses used restricted maximum likelihood estimation with Hartung-Knapp adjustment. Certainty of evidence was assessed using GRADE.ResultsNine trials involving 3779 patients were included. Adding specific agents to ENZ improved rPFS (HR = 0.76; 95% CI, 0.62-0.94; p = 0.02) but did not significantly improve OS, PFS, or PSA progression. Combination therapy increased the risk of any adverse event (RR = 1.03; 95% CI, 1.01-1.06) and grade ≥3 adverse events (RR = 1.37; 95% CI, 1.09-1.71). Estimates for individual adverse events were inconsistent and imprecise.ConclusionAdding specific agents to ENZ improved pooled rPFS but increased toxicity, without clear evidence of an OS benefit in unselected mCRPC populations (certainty of evidence ranging from very low to moderate across outcomes). These findings should be interpreted cautiously and do not exclude potential benefits from particular combinations in biomarker-selected populations.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261497638"},"PeriodicalIF":1.3,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149298228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug-induced QT prolongation in oncology: A precision-medicine.","authors":"Abdullah A Assiri","doi":"10.1177/10781552261503489","DOIUrl":"https://doi.org/10.1177/10781552261503489","url":null,"abstract":"<p><p>IntroductionProlongation of the heart-rate-corrected QT interval (QTc) is a defining safety concern in oncology, where patients face an expanding array of repolarization-altering agents superimposed on supportive drugs, electrolyte disturbgances, and organ dysfunction. The anchoring event, torsade de pointes, is uncommon but potentially lethal, and arrhythmic risk must be balanced against the survival benefit of effective cancer therapy.MethodsThe literature was identified through structured searches of PubMed, Scopus, and Web of Science covering the mechanistic, drug-class, pharmacovigilance, pharmacogenomic, risk-prediction, and management aspects of drug-induced QT prolongation in oncology, and was synthesized narratively with an emphasis on precision-medicine dimensions.ResultsQT liability is heterogeneous across tyrosine kinase inhibitors, cyclin-dependent kinase 4/6 inhibitors, antibody-drug conjugates, arsenic trioxide, and supportive agents such as antiemetics, antifungals, opioids, and antibiotics, and is frequently amplified by electrolyte derangement and drug-drug interactions. Genetic susceptibility, real-world pharmacovigilance, and machine-learning risk prediction are emerging but remain underdeveloped in oncology. Pragmatic management rests on baseline and serial Fridericia-corrected electrocardiography, electrolyte optimization, judicious agent selection and dose modification, medication review within a multidisciplinary team, and selection of structured lower-risk alternatives.ConclusionsDrug-induced QT prolongation in oncology is manageable rather than inevitable. Combining genomic susceptibility, pharmacovigilance, and validated prediction tools offers a route to individualized risk stratification, although prospective oncology-specific evidence and data from under-represented populations remain limited. Early identification and disciplined monitoring allow clinicians to protect the heart without compromising effective cancer treatment.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261503489"},"PeriodicalIF":1.3,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149298230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-ICU medication vulnerability and healthcare-access barriers associated with unplanned intensive care admission among cancer patients: A case-control study.","authors":"Ameerunnisha Begum, Allen Kuriakose, Shaba Chinnu Thomas","doi":"10.1177/10781552261503088","DOIUrl":"https://doi.org/10.1177/10781552261503088","url":null,"abstract":"<p><p>BackgroundUnplanned intensive care unit (ICU) admission is a critical event in the cancer trajectory and is associated with substantial mortality. Medication-related vulnerabilities and healthcare-access barriers may contribute to acute deterioration but remain insufficiently studied together.ObjectiveTo identify medication-related and healthcare-access factors independently associated with unplanned ICU admission among adults with cancer.MethodsThis hospital-based case-control study was conducted at a tertiary oncology centre. Cases were adults with cancer with unplanned ICU admission (n = 150), and controls were adults with cancer admitted to wards or day-care units without ICU requirement (n = 150), frequency-matched by age group, sex, and cancer type. Medication vulnerabilities and healthcare-access barriers were assessed using medical records and structured interviews. Multivariable logistic regression was performed to estimate adjusted odds ratios (aORs) with 95% confidence intervals (CIs).ResultsCases had higher prevalence of polypharmacy (64.0% vs 38.7%), clinically significant drug-drug interactions (42.0% vs 20.7%), and medication non-adherence (51.3% vs 29.3%). Financial barriers (58.7% vs 34.7%) and delayed care-seeking (46.0% vs 24.0%) were also more frequent. After adjustment, financial barriers (aOR 2.31, 95% CI 1.34-3.99), drug-drug interactions (2.14, 1.19-3.85), delayed care-seeking (2.08, 1.16-3.72), polypharmacy (2.05, 1.21-3.47), and non-adherence (1.94, 1.12-3.36) remained independently associated with unplanned ICU admission. ICU mortality was 32.0%.ConclusionMedication vulnerabilities and healthcare-access barriers were associated with unplanned ICU admission. These findings identify potentially modifiable areas for further evaluation, but the case-control design does not establish that interventions targeting these factors would directly reduce ICU admissions.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261503088"},"PeriodicalIF":1.3,"publicationDate":"2026-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149298196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When hospital pharmacies procure medicines for industry-sponsored oncology trials: The hidden costs of sponsor reimbursement.","authors":"Celeste Cagnazzo, Grazia Ceravolo, Francesco Maria Rossini, Alessio De Simone, Samantha Gomboso","doi":"10.1177/10781552261503984","DOIUrl":"https://doi.org/10.1177/10781552261503984","url":null,"abstract":"","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261503984"},"PeriodicalIF":1.3,"publicationDate":"2026-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149298248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Administration-related reactions following first-dose subcutaneous daratumumab to inform implementation of a 30-minute observation period.","authors":"Jennifer Galvet, Sara S Kim, Jessica Caro, David J Chung","doi":"10.1177/10781552261503888","DOIUrl":"https://doi.org/10.1177/10781552261503888","url":null,"abstract":"<p><p>IntroductionSubcutaneous daratumumab has lower rates of administration-related reactions (ARRs) than intravenous daratumumab and shorter administration times. However, the optimal monitoring following the first dose remains uncertain and varies across institutions. This medication use evaluation assessed first-dose ARRs under a 2-h observation protocol and whether available findings support reduced 30-min observation.MethodsThis retrospective, single-center cohort study included patients who received first-dose subcutaneous daratumumab at the Zuckerberg Cancer Center between March 6, 2024, and July 31, 2025. The primary endpoint was ARR incidence. Secondary endpoints included time to onset, CTCAE version 6.0 severity, and management interventions. Premedication adherence and potential chair-time savings from reducing observation from 4 to 2 h were also evaluated. After implementation of the 30-min observation period, 26 additional patients treated from April through June 2026 were reviewed for ARRs.ResultsAmong 50 patients in the primary cohort, one experienced an ARR (2%). Grade 3 ARR occurred 150 min after administration and required intravenous methylprednisolone, diphenhydramine, famotidine, and intramuscular epinephrine. Premedication deviations included diphenhydramine 25 mg instead of 50 mg and omitted montelukast. The patient tolerated subsequent doses after receiving the complete regimen. No ARRs occurred among the 26 patients evaluated after implementation of 30-min observation.ConclusionFirst-dose subcutaneous daratumumab was associated with a low ARR incidence, with the only reaction occurring beyond 2 h. Together with published evidence and institutional experience, these findings supported implementation of 30-min observation, with no ARRs observed after implementation. Larger studies with longer follow-up are warranted to further assess abbreviated observation.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261503888"},"PeriodicalIF":1.3,"publicationDate":"2026-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149298180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}